全文获取类型
收费全文 | 6281篇 |
免费 | 463篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 53篇 |
儿科学 | 205篇 |
妇产科学 | 141篇 |
基础医学 | 966篇 |
口腔科学 | 96篇 |
临床医学 | 671篇 |
内科学 | 1171篇 |
皮肤病学 | 165篇 |
神经病学 | 682篇 |
特种医学 | 162篇 |
外科学 | 624篇 |
综合类 | 51篇 |
一般理论 | 11篇 |
预防医学 | 623篇 |
眼科学 | 114篇 |
药学 | 408篇 |
中国医学 | 9篇 |
肿瘤学 | 611篇 |
出版年
2023年 | 94篇 |
2022年 | 70篇 |
2021年 | 210篇 |
2020年 | 207篇 |
2019年 | 266篇 |
2018年 | 265篇 |
2017年 | 222篇 |
2016年 | 238篇 |
2015年 | 229篇 |
2014年 | 306篇 |
2013年 | 390篇 |
2012年 | 591篇 |
2011年 | 547篇 |
2010年 | 270篇 |
2009年 | 276篇 |
2008年 | 418篇 |
2007年 | 406篇 |
2006年 | 361篇 |
2005年 | 335篇 |
2004年 | 279篇 |
2003年 | 245篇 |
2002年 | 223篇 |
2001年 | 27篇 |
2000年 | 16篇 |
1999年 | 15篇 |
1998年 | 24篇 |
1997年 | 14篇 |
1996年 | 12篇 |
1995年 | 15篇 |
1994年 | 17篇 |
1993年 | 18篇 |
1992年 | 10篇 |
1991年 | 7篇 |
1990年 | 7篇 |
1989年 | 3篇 |
1988年 | 10篇 |
1987年 | 4篇 |
1986年 | 6篇 |
1985年 | 9篇 |
1984年 | 4篇 |
1983年 | 6篇 |
1982年 | 9篇 |
1981年 | 11篇 |
1980年 | 9篇 |
1979年 | 4篇 |
1977年 | 4篇 |
1969年 | 6篇 |
1958年 | 3篇 |
1954年 | 3篇 |
1926年 | 3篇 |
排序方式: 共有6763条查询结果,搜索用时 15 毫秒
1.
Huebner Lucas Schroeder Ines Kraft Eduard Gutmann Marcus Biebl Johanna Klamt Amrei Christin Frey Jana Warmbein Angelika Rathgeber Ivanka Eberl Inge Fischer Uli Scharf Christina Schaller Stefan J. Zoller Michael 《Der Anaesthesist》2022,71(10):795-800
Die Anaesthesiologie - Bei etwa 43?% aller Überlebenden der Intensivmedizin wird ein erworbenes Syndrom an Muskelschwäche beobachtet, welches Überleben und Lebensqualität... 相似文献
2.
Heramvand Nadia Masyuk Maryna Muessig Johanna M. Nia Amir M. Karathanos Athanasios Polzin Amin Valgimigli Marco Gurbel Paul A. Tantry Udaya S. Kelm Malte Jung Christian 《Journal of thrombosis and thrombolysis》2022,54(2):301-308
Journal of Thrombosis and Thrombolysis - Tirofiban is a glycoproteine (GP) IIb/IIIa receptor antagonist, which inhibits platelet-platelet aggregation and is a potential adjunctive antithrombotic... 相似文献
3.
4.
5.
Collagens are the most abundant proteins in the extracellular matrix. They provide a framework to build organs and tissues and give structural support to make them resistant to mechanical load and forces. Several intra‐ and extracellular modifications are needed to make functional collagen molecules, intracellular post‐translational modifications of proline and lysine residues having key roles in this. In this article, we provide a review on the enzymes responsible for the proline and lysine modifications, that is collagen prolyl 4‐hydroxylases, 3‐hydroxylases and lysyl hydroxylases, and discuss their biological functions and involvement in diseases. 相似文献
6.
Max Henningsen Bernd Jaenigen Stefan Zschiedrich Przemyslaw Pisarski Gerd Walz Johanna Schneider 《Transplantation proceedings》2021,53(5):1589-1598
BackgroundLeukopenia is a common complication after kidney transplantation. The etiology is multifactorial, with medication adverse effects and cytomegalovirus infection as main causes. Optimal strategies to prevent or treat posttransplant leukopenia remain unknown. We aimed to identify risk factors for leukopenia and to investigate the benefit of switching the immunosuppressive therapy to hydrocortisone as a continuous infusion.MethodsWe retrospectively evaluated all patients with leukopenia after kidney transplantation between 2007 and 2017 at our center relative to age- and sex-matched controls.ResultsLeukopenia was associated with the degree of rejection therapy before leukopenia, the immunosuppressive therapy before transplantation, and an induction therapy with rabbit antithymocyte globulin. Patients with leukopenia exhibited increased mortality, an increased incidence of bacterial and viral infections, and more acute rejections. Switching to hydrocortisone as a continuous infusion in patients with severe leukopenia decreased the duration of leukopenia and the incidence of subsequent viral infections, especially with cytomegalovirus.ConclusionLeukopenia is a risk factor for infectious complications and mortality, and it is associated with acute rejection. Switching immunosuppressive therapy to hydrocortisone as a continuous infusion is a safe approach to reduce the duration of leukopenia and the incidence of viral infections. 相似文献
7.
Monica Poiani Myriam Labopin Giorgia Battipaglia Dietrich W. Beelen Johanna Tischer Jürgen Finke Arne Brecht Edouard Forcade Arnold Ganser Jakob R. Passweg Helene Labussiere‐Wallet Ibrahim Yakoub‐Agha Kerstin Schfer‐Eckart Nicolaus Kroeger Blandine Guffroy Annalisa Ruggeri Jordi Esteve Arnon Nagler Mohamad Mohty 《American journal of hematology》2021,96(1):40-50
Karyotypic analysis at time of diagnosis has an important value in determining initial response to treatment, remission duration and overall survival (OS) in acute myeloid leukemia (AML). Less is known about its value before allogeneic hematopoietic cell transplantation (allo‐HCT) in patients transplanted with active disease, either relapsed or primary refractory (Rel‐Ref) AML. We explored the impact of cytogenetic risk (stratification according to MRC‐UK) in 2089 patients with either Ref (n = 972) or Rel AML (n = 1117) transplanted during the period 2000‐2017. Overall, 154 patients had a favorable risk, 1283 had an intermediate risk and 652 had an adverse cytogenetic risk. Median follow‐up was 49 months. Compared to the favorable risk group, intermediate and adverse risk patients were associated with worse leukemia‐free survival and OS and also with a higher incidence of relapse. In a subgroup analysis of patients in the intermediate risk group harboring Fms‐like tyrosine kinase 3‐internal tandem duplication (FLT3‐ITD), this remained an important prognostic factor, being associated with worse outcomes. When analyzing patients according to the intensity of the conditioning regimen, no differences were observed for the main transplant outcomes. In conclusion, in patients diagnosed with AML and transplanted with active disease, karyotype remains an important prognostic factor, allowing splitting patients into different risk groups according to their cytogenetics. Similarly, FLT3‐ITD mutation also remains a negative prognostic factor in this population. 相似文献
8.
9.
10.
Filippo Pietrantonio Giovanni Fucà Daniele Rossini Hans-Joachim Schmoll Johanna C. Bendell Federica Morano Carlotta Antoniotti Salvatore Corallo Beatrice Borelli Alessandra Raimondi Federica Marmorino Monica Niger Alessandra Boccaccino Gianluca Masi Sara Lonardi Luca Boni Filippo de Braud Maria Di Bartolomeo Alfredo Falcone Chiara Cremolini 《The oncologist》2021,26(4):302-309
BackgroundDoublets plus anti‐epidermal growth factor receptors (EGFRs) are the preferred upfront option for patients with left‐sided RAS/BRAF wild‐type metastatic colorectal cancer (mCRC). Initial therapy with FOLFOXIRI‐bevacizumab is superior to doublets plus bevacizumab independently from primary tumor sidedness and RAS/BRAF status. No randomized comparison between FOLFOXIRI‐bevacizumab versus doublets plus anti‐EGFRs is available in left‐sided RAS/BRAF wild‐type mCRC.Materials and MethodsWe selected patients with left‐sided RAS and BRAF wild‐type mCRC treated with first‐line FOLFOX‐panitumumab or FOLFOXIRI‐bevacizumab in five randomized trials: Valentino, TRIBE, TRIBE2, STEAM, and CHARTA. A propensity score‐based analysis was performed to compare FOLFOXIRI‐bevacizumab with FOLFOX‐panitumumab.ResultsA total of 185 patients received FOLFOX‐panitumumab and 132 received FOLFOXIRI‐bevacizumab. Median progression‐free survival (PFS) and median overall survival (OS) were 13.3 and 33.1 months in the FOLFOXIRI‐bevacizumab group compared with 11.4 and 30.3 months in the FOLFOX‐panitumumab group (propensity score‐adjusted hazard ratio (HR) for PFS, 0.82; 95% confidence interval (CI), 0.64–1.04; p = .11; propensity score‐adjusted HR for OS, 0.80; 95% CI, 0.59–1.08; p = .14). No significant differences in overall response rate and disease control rate were observed. A statistically nonsignificant difference in favor of FOLFOXIRI‐bevacizumab was observed for OS after secondary resection of metastases. Chemotherapy‐related adverse events were more frequent in the FOLFOXIRI‐bevacizumab group, with specific regard to grade 3 and 4 neutropenia (48% vs. 26%, adjusted p = .001).ConclusionAlthough randomized comparison is lacking, both FOLFOXIRI‐bevacizumab and FOLFOX‐panitumumab are valuable treatment options in left‐sided RAS/BRAF wild‐type mCRC.Implications for PracticeA propensity score‐based analysis of five trials was performed to compare FOLFOX‐panitumumab versus FOLFOXIRI‐bevacizumab in left‐sided RAS/BRAF wild‐type metastatic colorectal cancer (mCRC). No significant differences were observed, but FOLFOXIRI‐bevacizumab achieved numerically superior survival outcomes versus FOLFOX‐panitumumab. Chemotherapy‐related adverse events were more frequent in the FOLFOXIRI‐bevacizumab group. These observations suggest that although doublet chemotherapy plus anti‐EGFRs remains the preferred treatment in patients with left‐sided RAS/BRAF wild‐type mCRC, FOLFOXIRI‐bevacizumab is a valuable option able to provide similar, if not better, outcomes at the price of a moderate increase in toxicity and may be adopted based on patients’ preference and potential impact on quality of life. 相似文献